Breaking News, Collaborations & Alliances

NIAID, BioCryst Exercise Development Option

Aims to advance drug for Marburg virus through Phase I

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The National Institute of Allergy and Infectious Diseases (NIAID) has exercised an option under its agreement with BioCryst Pharmaceuticals for the conduct of an IND program for the development of BCX4430 as a treatment for Marburg virus disease. BioCryst will receive an additional $2.5 million, which follows an initial award of $5.0 million in September 2013. The total funding could reach $22.0 million during the next five years.   The goal of the contract is to file INDs for intravenous and in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters